Ep. 359 - 2Q markets preview, tariffs and biotech takeouts

April 6, 2026·39 min·2 clips

Will the Middle East conflict stop biotech's recovery in its tracks, just as the sector closed March with over $20 billion in deal-making?

1. BioCentury This Week delivers a second-quarter public markets preview hosted by Jeff with analysts Stephen Hansen, Steve Uzzin, Simone Fishburne, and Lauren Martz. 2. Stephen Hansen conducted buy-side and banker conversations over several weeks to build the Q2 outlook, while Steve Uzzin covers Washington policy and Lauren Martz covers M&A and deals. 3. The episode's core thesis is that biotech entered Q2 with strong fundamental momentum—nine Q1 deals totaling $32 billion—but a new Middle East conflict has placed a significant cloud of uncertainty over the sector's trajectory. 4. Hansen describes a two-scenario framework: if the conflict resolves quickly, biotech returns to its Q1 trajectory; if prolonged, rising oil prices drive inflation and interest rates higher, which historically pressures the sector, especially SMID caps. 5. Q1 biotech outperformance was driven by M&A activity at a steady cadence, positive clinical readouts rewarded by the market, and multiple financing deals upsized from initial targets—some from $400 million to $650 million—indicating generalist fund inflows. 6. IPOs are considered the most vulnerable segment to volatility, with the expectation they remain effectively on hold until macro uncertainty subsides, while M&A continues. 7. Steve Uzzin explains Trump's announced pharma tariff structure: up to 100% on patented drug imports and APIs, implemented over 120-180 days, with exemptions for generics, biosimilars, orphan drugs, and companies signing MFN deals. 8. The structural asymmetry Uzzin highlights: MFN deals sunset at the end of the Trump administration, while the tariffs have no sunset, giving the administration permanent leverage over mid-sized biotechs dependent on overseas manufacturing in Ireland and China. 9. A 'specialty drug' exemption can be granted by the Secretary of Commerce, which Uzzin characterizes as opening a vector for political lobbying and potential favoritism. 10. Trade associations including BIO and PhRMA have issued statements against the tariffs, but the Trump administration explicitly excluded them from MFN negotiations, dealing only with individual companies. 11. Uzzin notes that legal challenges to the tariffs are likely but uncertain in outcome, and that companies cannot assume they will be thrown out given the specific legal basis being used. 12. Vinay Prasad's departure from CBER is discussed: investors hope it signals a return to predictable FDA review pathways, but Uzzin reports companies are meeting with the FDA chief counsel—unusual for pending applications—suggesting FDA is looking for approval pathways for products that received CRLs under Prasad's influence. 13. Eli Lilly's $6.3 billion acquisition of Syntesa drew analyst attention because the contingent value right milestones are all tied to indications outside narcolepsy type 1, signaling Lilly's thesis is broader chronic sleep disorder and neurological comorbidity markets. 14. Lauren Martz explains the mechanistic tipping point: Syntesa's phase 2 data in narcolepsy type 2 and idiopathic hypersomnia shows OX2R agonism improves wakefulness even when orexin neurons are present and active, not just in patients with neuron loss. 15. The Syntesa deal is Lilly's largest since it acquired Loxo for $7.2 billion in 2019; other 2024 Lilly deals include Orna Therapeutics (circular RNA/in vivo CAR T), Ventex (NLRP3 inhibitors), and a $350 million upfront pipeline deal with InnoVent. 16. Biogen acquired Apellis for $5.6 billion upfront, gaining two formulations of pegcetacoplan—one covering PNH plus two nephrology indications, one approved for geographic atrophy—which generated just under $700 million in 2025. 17. Stephen Hansen calculates an implied 4.7x 2028 peak sales multiple for Biogen's Apellis acquisition and questions whether moderate mid-teen growth through 2028 constitutes the 'strong growth driver' Biogen framed it as; the stock fell 5% on announcement. 18. Hansen's read is that Biogen has used its one large-deal firepower for the near term, though CEO Chris Viehbacher stated on the analyst call that Apellis was the best strategic fit among all companies reviewed under $5 billion market cap. 19. Investors focused on strategy and portfolio construction who follow biotech M&A cycles, tariff policy, and FDA regulatory dynamics will find this episode directly actionable. 20. General science or early-stage startup listeners without background in biotech capital markets will likely find the depth of deal analysis and policy nuance inaccessible.

As heard by us

Biotech dealmaking keeps moving, but the recovery still depends on policy and regulatory steadiness.

BioCentury This Week presents biotech as steadier than the headlines suggest: markets remain unsettled, yet M&A and financing activity keep moving, and that balance is the point.

Read the full review in PlayNext →

Why you'd press play

You want a clean read on biotech dealmaking, threatened tariffs, and the public-market mood.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from BioCentury This Week